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Abstract
Introduction: Septic shock remains a major health care problem worldwide. Sepsis-induced immune alterations
are thought to play a major role in patients’ mortality and susceptibility to nosocomial infections. Programmed
death-1 (PD-1) receptor system constitutes a newly described immunoregulatory pathway that negatively controls
immune responses. It has recently been shown that PD-1 knock-out mice exhibited a lower mortality in response
to experimental sepsis. The objective of the present study was to investigate PD-1-related molecule expressions in
septic shock patients.
Methods: This prospective and observational study included 64 septic shock patients, 13 trauma patients and 49
healthy individuals. PD-1-related-molecule expressions were measured by flow cytometry on circulating leukocytes.
Plasmatic interleukin (IL)-10 concentration as well as ex vivo mitogen-induced lymphocyte proliferation were
assessed.
Results: We observed that septic shock patients displayed increased PD-1, PD-Ligand1 (PD-L1) and PD-L2
monocyte expressions and enhanced PD-1 and PD-L1 CD4
+ T lymphocyte expressions at day 1-2 and 3-5 after the
onset of shock in comparison with patients with trauma and healthy volunteers. Importantly, increased expressions
were associated with increased occurrence of secondary nosocomial infections and mortality after septic shock as
well as with decreased mitogen-induced lymphocyte proliferation and increased circulating IL-10 concentration.
Conclusions: These findings indicate that PD-1-related molecules may constitute a novel immunoregulatory
system involved in sepsis-induced immune alterations. Results should be confirmed in a larger cohort of patients.
This may offer innovative therapeutic perspectives on the treatment of this hitherto deadly disease.
Introduction
Sepsis remains a major health-care problem worldwide
[1]. For example, during the last decade, its hospitaliza-
tion rate has almost doubled in the US [2]. This is asso-
ciated with a mortality rate approaching 50% in the case
of septic shock [3,4], despite the development of novel
treatments such as early appropriate antibiotherapy,
early goal-directed therapy, and activated protein C.
Therefore, a better understanding of pathophysiology of
severe sepsis is a necessity if we are to decrease the high
mortality rate of this condition.
Septic pathophysiology is a culmination of multiple
complex dynamic processes whose interactions are only
partially understood. However, it is now accepted that
after a rapid proinflammatory response, a counter-
regulatory phase characterized by immune alterations
impacting both innate and adaptive responses develops
[1,5,6]. This second phase has been characterized by an
increased production of anti-inflammatory cytokines
(mainly interleukin-10 (IL-10) and transforming growth
factor-beta) [7], increased lymphocyte apoptosis [8],
increased proportion of circulating regulatory T cells
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expression [10]. However, much remains to be under-
stood in order to clarify our vision of this complex and
multiparameter pathophysiologic process.
Programmed death-1 (PD-1)-related molecules consti-
tute a complex system of negative regulators involved in
controlling T-cell responses. This system is composed of
PD-1 (CD279) and its two ligands, PD-L1 (B7-H1,
CD274) and PD-L2 (B7-DC, CD273). These molecules
belong to the B7:CD28 family [11]. They are best under-
stood relative to their role in viral infections and oncol-
ogy [11-14]. It has been proposed that pathogens and
tumor cells may take advantage of this pathway to
escape the host’s immune defenses. Considering their
immunoregulatory properties, we postulated that the
PD-1 system could participate in sepsis-induced
immune dysfunctions. Indeed, it was recently shown
that PD-1 knockout mice exhibited not only a greater
capacity to clear bacteria but, more importantly, a lower
mortality in response to experimental sepsis [15]. There-
fore, the objective of this study was to investigate the
PD-1 system in patients with septic shock.
Materials and methods
Patients
After Hospices Civils de Lyon (Lyon, France) ethics
committee review and approval, we enrolled 64 patients
with septic shock in this observational clinical study
( f r o m2 0 0 7t o2 0 0 9 ) .S e p t i cs h o c kw a sd i a g n o s e d
according to the diagnostic criteria of the American
College of Chest Physicians/Society of Critical Care
Medicine [16]. Patients were admitted to one of the two
intensive care units (ICUs) (one medical, the other sur-
gical) of the Lyon-Sud University Hospital (France).
Septic shock was defined by an identifiable site of
infection, which was evidence of a systemic inflamma-
tory response manifested by at least two of the following
criteria: (a) temperature of greater than 38°C or less
than 36°C, (b) heart rate of greater than 90 beats per
minute, (c) respiratory rate of greater than 20 breaths
per minute, and (d) white blood cell count of greater
than 12,000 or less than 4,000/mm
3 and hypotension
persisting despite fluid resuscitation and requiring vaso-
pressor therapy. The beginning of vasopressive therapy
was considered the time of diagnosis of septic shock.
Exclusion criteria were age of less than 18 years and the
absence of circulating leukocytes for flow cytometry
phenotyping. No patients with HIV were included.
Patients with cancer were excluded from our study if
they presented with an aplasia (defined by a polymor-
phonuclear neutrophil count of less than 0.5 G/L) or
were treated with a high dose of corticoids (estimated as
treatment superior to 10 mg equivalent prednisolone/
day or more than 700 mg equivalent prednisolone
accrued the first day of inclusion) or both.
The following clinical and biological data were collected:
demographic characteristics (age and gender), admission
category (elective or emergency surgery and medicine),
referral pattern (community-, hospital-, or ICU-acquired
septic shock), microbiological findings, clinical scores
(Simplified Acute Physiology Score II (SAPS II) and sep-
sis-related organ failure assessment (SOFA) score),
incidence of secondary nosocomial infections (defined
as microbiologically documented pulmonary infection,
urinary tract infection, bloodstream infection, and cathe-
ter-related infection that occurred 48 hours after ICU
admission and up to ICU discharge [17]), and the outcome
after 28 days (death or survival).
The protocol was reviewed by the institutional ethics
committee, which waived the need for informed consent
because the study was observational and involved sam-
pling of very small quantities of blood. The purpose of
the study was explained to the patients or members of
their families. Samples were collected from residual
blood after completion of routine follow-up. Ethylene-
diaminetetraacetic acid (EDTA)-anti-coagulated blood
was collected from patients at different time points: day
(D) 1-2, D3-5, and D6-10 after diagnosis of septic shock.
Additionally, 13 trauma patients were included in the
study within the first 48 hours of admission. Inclusion
criteria were trauma, age of at least 18 years, and an
initial injury severity score (ISS) of at least 25. Finally,
49 healthy volunteers from laboratory staff of our hospi-
tal were included as controls.
Flow cytometry reagents
The following antibodies were used: PC5-labeled anti-
CD4, PC5-labeled anti-CD8, PC5-labeled anti-CD14,
PC5-labeled anti-CD25, PE-labeled anti-CD127, FITC-
labeled anti-CD14, ECD-labeled anti-CD4 (Beckman
Coulter, Miami, FL, USA), and PE-labeled anti-HLA-DR
or its isotype PE-labeled IgG2a (Becton-Dickinson Bios-
ciences, San Jose, CA, USA), PE-labeled anti-human
CD249 (PD-1, clone MIH4), FITC-labeled anti-human
CD274 (PD-L1, clone MIH1), or PE-labeled anti-human
CD273 (PD-L2, clone MIH18) (BD Biosciences). Red
blood cells were lysed using the automated TQ-Prep
(Beckman Coulter) or using FACS-lysing solution (BD
Biosciences). Samples were run on FC500 (Beckman
Coulter) and analyzed using CXP software (Beckman
Coulter).
Plasma cytokine measurements
IL-10 concentration in patients’ plasma samples was mea-
sured by Bio-Plex Pro Assays (Bio-Rad Laboratories, Inc.,
Hercules, CA, USA). Unknown sample values presented
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human standards as described by the manufacturer.
Cell isolation, culture conditions, and cell proliferation
assay
In brief, peripheral blood mononuclear cells (PBMCs)
were isolated by Ficoll density gradient centrifugation
(PAA Laboratories, Pasching, Austria). PBMCs were
washed three times in phosphate-buffered saline (bio-
Mérieux, Marcy-l’Etoile, France) and resuspended in
complete medium - that is, RPMI supplemented with
HEPES (25 mM), sodium bicarbonate (2 g/L) (Eurobio
Laboratories, Les Ulis, France), 10% human serum
AB (obtained from a pool of healthy volunteers), 2 mM
L-glutamine (Lonza, Verviers, Belgium), 20 UI/mL peni-
cillin, 20 μg/mL streptomycin (Sigma-Aldrich, St. Louis,
MO, USA), and 2.5 μg/mL Amphotericin B (Bristol-
Myers Squibb Company, Princeton, NJ, USA). Cells
were kept on ice until stainings or cell cultures were
performed.
PBMCs were seeded at a density of 1 × 10
6 cells/mL
(50,000 cells/well, 100 μL) in flat-bottom 96-well micro-
titer plates and were stimulated with 5 μg/mL phytohe-
magglutinin (PHA) (Remel, part of Thermo Fisher
Scientific, Lenexa, KS, USA). Cells were incubated
48 hours at 37°C in a humidified 5% CO2 atmosphere.
[methyl-
3H]-Thymidine (20 μCi/mL) (PerkinElmer,
Waltham, MA, USA) was added 24 hours before har-
vesting cells on fiberglass filters by means of an auto-
mated cell harvester (PerkinElmer). Incorporated
radioactivity was measured in a direct beta counter (Per-
kinElmer). Assays were carried out in triplicate.
Data analysis and statistics
Patients’ clinical and biological parameters were pre-
sented as frequencies, percentages, medians, and inter-
quartile ranges (IQRs). Differences in expression levels
were calculated using the Mann-Whitney U test or,
when multiple comparisons were performed, the Fried-
man test. Correlations were calculated using the Spear-
man rank test. P values of not more than 0.05 were
considered statistically significant; if necessary, correc-
tion for the number of tests was performed. Statistical
analysis was performed using SPSS software (version
12.0; SPSS Inc., Chicago, IL, USA).
Results
Clinical characteristics of the patient population
Sixty-four patients with septic shock (20 women and 44
men) were included in the study. Their clinical charac-
teristics are shown in Table 1. Median age at admission
was 63 years (IQR 54 to 73). Median values for SAPS II
and SOFA score at diagnosis of shock were 53 (IQR 39
to 64) and 10 (IQR 8 to 12), respectively, indicating a
high level of severity. Approximately 30% of patients
developed secondary nosocomial infections, and 28-day
mortality was 17%.
Septic patients presented with typical features of sepsis-
induced immunosuppression and displayed a reduced
monocyte HLA-DR expression at D3-5 (median value
45.5%, IQR 29.5 to 69.5) in comparison with control
values (>90% [18]). Median CD4
+ T-cell count was also
decreased in patients in comparison with healthy
Table 1 Clinical characteristics of the patients with septic
shock
Parameters Patients with septic
shock
(n = 64)
Age at admission, years 63 (54-73)
Males, number (percentage) 44 (68.8)
SAPS II at diagnosis of shock 53 (39-64)
Main admission category, number
(percentage)
Medical 25 (39.1)
Surgery + trauma 39 (60.9)
Comorbidities, number (percentage) of
patients
None 35 (54.7)
One or more 29 (45.3)
SOFA score at diagnosis of shock 10 (8-12)
28-day non-survivors, number (percentage) 11 (17.2)
Infection, number (percentage)
Diagnosis
Radiology 10 (15.6)
Surgery 7 (10.9)
Microbiologically documented
Bacilli Gram-negative 26 (40.6)
Cocci Gram-positive 30 (46.9)
Fungi 8 (12.5)
Type of infection
Community-acquired 38 (59.4)
Nosocomial 26 (40.6)
Site of infection
Pulmonary 21 (32.8)
Abdominal 27 (42.2)
Others 16 (25)
Secondary nosocomial infections, number
(percentage)
19 (29.7)
Immunological parameters
Percentage mHLA-DR
a 45.5 (29.5-69.5)
CD4
+ T-cell counts, cells/μL
a 319 (226-681)
Percentage of regulatory T cells
a 8.5 (6.1-11.2)
Values are presented as median and interquartile range (IQR) for continuous
variables or as number of cases and percentage for categorical data.
aMeasured at day 3 to 5 after the onset of septic shock. CD4
+ T-cell counts
were measured in 41 patients with septic shock, and percentage of regulatory
T cells (CD4
+CD25
+CD127
-) was measured in 42 patients. mHLA-DR, monocyte
HLA-DR; SAPS II, Simplified Acute Physiology Score II; SOFA, sepsis-related
organ failure assessment.
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cells/μL (IQR 679 to 1,075), respectively; P < 0.001),
whereas percentage of circulating regulatory T cells (CD4
+CD25
+CD127
- T lymphocytes) was augmented (8.5%
(IQR 6.1% to 11.2%) versus 6.2% (IQR 5.2% to 7.6%),
respectively; P = 0.001).
Thirteen trauma patients (9 men and 4 women) were
also included in the study. Median age at admission was
34 years (IQR 24 to 56). In the first 24 hours of admis-
sion, they presented a median ISS of 32 (IQR 26 to 34)
and a median SAPS II of 39 (IQR 22 to 52).
PD-1-related molecule expression in patients with
septic shock
PD-1, PD-L1, and PD-L2 expressions were measured on
circulating CD4
+ lymphocytes, CD8
+ lymphocytes (PD-1
only), and monocytes at D1-2 and 3-5 after the onset of
septic shock. Results for CD4
+ lymphocytes and mono-
cytes are shown in Figure 1.
The percentages of circulating monocytes expressing
PD-1, PD-L1, or PD-L2 were markedly increased in
patients with septic shock in comparison with healthy
volunteers during the overall monitoring (Figure 1a).
This augmentation was present for PD-1 (median con-
trol values: 5.0% versus 18.6% (D1-2) and 17.8% (D3-5)
in patients; P < 0.001), for PD-L1 (control values: 10.2%
versus 46.6% (D1-2) and 34.9% (D3-5) in patients; P <
0.001), and for PD-L2 (control values: 2.6% versus 8.7%
(D1-2) and 8.5% (D3-5) in patients; P < 0.001). Similar
results were observed when flow cytometry data were
expressed as mean fluorescence intensity (MFI) (Table
2). In trauma patients, PD-1-related molecule expres-
sions on monocytes were significantly increased in com-
parison with healthy individuals (for PD-1: control
value: 5.0% versus 9.6%, P = 0.005; for PD-L1: control
value: 10.2% versus 40.1%, P < 0.001; and for PD-L2:
control value: 2.6% versus 7.2%, P < 0.001). However,
PD-1 expression on monocytes was significantly lower
in trauma than in septic shock patients at D1-2 (9.6%
versus 18.6%, respectively; P = 0.008) (data not shown).
Likewise, the percentages of circulating CD4
+ lympho-
cytes expressing PD-1 or PD-L1 were notably increased
in patients with septic shock in comparison with healthy
volunteers during the overall monitoring (for PD-1: con-
trol values: 5.4% versus 15.0% (D1-2) and 13.6% (D3-5),
P < 0.001; for PD-L1: control values: 2.5% versus 3.9%
(D1-2; P = 0.002) and 3.6% (D3-5; P = 0.016) in
patients) (Figure 1b). Alternatively, no significant differ-
ences were observed between patients and healthy
volunteers for percentages of CD4
+ cells expressing PD-
L2 (Figure 1b) or of CD8
+ lymphocytes positive for PD-
1 (Table 2). Once again, similar results were observed
when flow cytometry results were expressed as MFI
(Table 2). No difference in PD-1-related molecule
expressions was observed between trauma patients and
healthy individuals. However, the percentage of PD-1
expressing CD4
+ cells was significantly lower in trauma
than in septic shock patients at D1-2 (5.2% versus
15.0%, respectively; P < 0.001) (data not shown).
Of note, there was no variation of PD-1-related mole-
cule expressions in regard to age or gender either in
healthy subjects or in patients with septic shock. Indeed,
we did not observe significant correlations between PD-
1-related molecule expressions and the age of septic
shock patients (r =0 . 2 1 ,P = 0.12 for PD-1 expression
on CD4
+ lymphocytes; r = 0.04, P =0 . 7 8f o rP D - L 1
expression on monocytes) or of healthy volunteers (r =
0.10, P = 0.49 for PD-1 expression on CD4
+ lympho-
cytes; r = -0.15, P = 0.30 for PD-L1 expression on
monocytes).
Finally, in 10 patients with septic shock, sequential
blood samples were obtained at D1-2, D3-5, and D6-10
after the onset of shock. During this period, no signifi-
cant variations over time in regard to PD-1 molecule
expressions either on monocytes or on lymphocytes
were observed (Figure 2).
Association between PD-1-related molecule expressions
and clinical parameters
To assess the clinical relevance of the increase in PD-1-
related molecule expressions after septic shock, flow
cytometric measurements were correlated with clinical
parameters and usual biomarkers of sepsis-induced
immunosuppression. No significant correlations were
found between PD-1-related molecule expressions and
percentages of HLA-DR expressing monocytes, CD4
+
lymphocyte count, percentage of circulating regulatory
T cells, or severity scores calculated at the onset of
shock (SAPS II or SOFA score) (data not shown). How-
ever, at D1-2, we observed that PD-L1 expression on
monocytes was significantly higher in non-survivors in
comparison with survivors (Figure 3a). Moreover, at D3-
5, patients who went on to develop a secondary nosoco-
mial infection presented with higher PD-1 (Figure 3b)
and PD-L2 (Figure 3c) expressions on their blood
monocytes in comparison with those who remained free
of any secondary nosocomial episode.
Correlation between plasma IL-10 concentration and
PD-1-related molecule expression in patients with
septic shock
Increased circulating IL-10 concentration has been linked
with mortality after septic shock [19] and recently with
enhanced PD-1 expression in HIV-infected patients [20].
We thus measured circulating IL-10 levels in 29 septic
shock patients for whom plasma samples were available
and we correlated this parameter with leukocyte PD-1/
PD-L expressions. Not surprisingly, we observed that
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tion than survivors at D1-2 and D3-5 (P = 0.01 for both)
(Figure 4a). Interestingly, a significant positive correlation
was measured between PD-1 monocyte expression and
plasma IL-10 concentration in patients at D1-2 (r = 0.49;
P = 0.007) (Figure 4b) but not at D3-5 (data not shown).
In addition, significant correlations were observed between
both PD-L1 or PD-L2 monocyte expressions and
increased plasma IL-10 concentration at D1-2 (r = 0.58;
P = 0.001 and r =0 . 4 5 ;P = 0.014, respectively) and D3-5
(r =0 . 4 5 ;P = 0.015 and r =0 . 5 3 ;P = 0.003, respectively)
(Figure 4c, d). Of note, no correlations were found
between PD-1/PD-L-related molecule expressions on
CD4
+ lymphocytes and changes in plasma IL-10 concen-
tration (data not shown). Also, for all of these observations
made for percentage of positive cells, similar correlations
were obtained when flow cytometry results were expressed
as MFI (data not shown).
CD4+ Lymphocytes
PD-1
0
10
20
30
40
50
Healthy 
volunteers
P
e
r
c
e
n
t
 
o
f
 
p
o
s
i
t
i
v
e
 
c
e
l
l
s
(77.1) (80.6)
PD-L1
Healthy 
volunteers
0
5
10
15
20
(27.5)
(28.2)
**
**
**
*
Septic shock patients
D1-2           D3-5
Septic shock patients
D1-2           D3-5
B
0
1
2
3
4
5
6 (6.6)
(21.2) (19.5)
Healthy 
volunteers
Septic shock patients
D1-2           D3-5
PD-L2
0
20
40
60
80
PD-1
Healthy 
volunteers
P
e
r
c
e
n
t
 
o
f
 
p
o
s
i
t
i
v
e
 
c
e
l
l
s
**
**
0
20
40
60
80
100
PD-L1
Healthy 
volunteers
PD-L2
0
10
20
30
40
(58.3)
(57.4) (63.8)
Healthy 
volunteers
Monocytes
**
**
**
**
Septic shock patients
D1-2           D3-5
Septic shock patients
D1-2           D3-5
Septic shock patients
D1-2           D3-5
A
Figure 1 PD-1, PD-L1, and PD-L2 measurements on circulating CD4
+ lymphocytes and monocytes in septic shock patients and healthy
volunteers. PD-1-related molecule expressions were measured on circulating monocytes (a) and CD4
+ lymphocytes (b) in whole blood from
healthy volunteers (n = 49) and septic shock patients at day 1 to 2 (D1-2) (n = 37) and at day 3 to 5 (D3-5) (n = 56) after the onset of shock.
Results are presented as percentages of positive cells among total population of monocytes or CD4
+ lymphocytes and as box-plots and
individual values. *P < 0.020, **P ≤ 0.002 (Mann-Whitney U test). A P value of less than 0.025 was considered statistically significant (with
correction for the number of tests). PD-1, programmed death-1; PD-L1, programmed death-ligand 1; PD-L2, programmed death-ligand 2.
Guignant et al. Critical Care 2011, 15:R99
http://ccforum.com/content/15/2/R99
Page 5 of 11Decreased lymphocyte proliferation after septic shock
In an attempt to begin to address the biological signifi-
cance of these changes in PD-1 expression to the devel-
opment of sepsis-induced lymphocyte dysfunction,
freshly isolated PBMCs from septic shock patients and
healthy volunteers were assessed for their capacity to
respond to PHA. As expected, we observed that lym-
phocyte proliferation was significantly reduced in
patients in comparison with healthy volunteers (P <
0.001) (Figure 5a). Interestingly, in patients, a significant
negative correlation was observed between this reduced
proliferation and PD-1 (r = -0.81 with P = 0.003) (Figure
5b) or PD-L1 (r = -0.63 with P = 0.039) (data not
shown) overexpression on circulating CD4
+ lympho-
cytes. Similar results were obtained when PD-1 and PD-
L1 staining was expressed as MFI (r = -0.80 with P =
0.003 and r = -0.63 with P = 0.038, respectively).
Discussion
PD-1 and its ligands, PD-L1 and PD-L2, belong to the
B7-CD28 family of molecules [11]. Co-ligation of T-cell
receptor with the PD-1 system is thought to induce an
inhibitory signal in T cells characterized by cell cycle
arrest, inability to proliferate, and reduced cytokine
synthesis (interferon-gamma (IFN-g)o rI L - 2o rb o t h
[21-24]). The co-inhibitory PD-1 system has been stu-
died mainly in viral diseases and oncology. This system
may be used by viral pathogens or cancer cells to evade
the host’si m m u n er e s p o n s e[ 1 1 ] .O fn o t e ,i nv i r u s -
infected patients, CD8
+ T cells overexpressing PD-1 (in
comparison with healthy volunteers) exhibit a so-called
‘exhaustion profile’ as they produced less IFN-g follow-
ing antigen stimulation, had reduced cytotoxic activity,
and had decreased proliferation in response to specific
antigens [25-27].
Table 2 PD-1-related molecule expressions as mean of fluorescence intensity on leukocytes in septic shock patients
and healthy volunteers
CD4
+ T cells CD8
+ T cells Monocytes
PD-1 PD-L1 PD-L2 PD-1 PD-1 PD-L1 PD-L2
Healthy volunteers Median 8.7 11.5 4.9 13.6 12.3 16.9 8.9
IQR (7.8-10.5) (10.1-12.0) (4.5-5.6) (11.1-20.4) (10.1-15.8) (15.3-18.2) (7.7-9.8)
Median 13.1 11.4 6.0 18.1 17.4 22.0 11.6
Day 1-2 IQR (11.4-19.7) (9.8-14.3) (4.8-7.1) (13.6-24.4) (14.6-24.0) (19.3-31.8) (9.9-13.6)
Septic shock patients P value <0.001 0.150 0.009 0.213 <0.001 <0.001 <0.001
Median 12.2 11.4 5.4 17.5 16.2 21.1 11.1
Day 3-5 IQR (10.8-15.7) (10.0-13.5) (4.4-7.1) (11.8-22.3) (13.0-20.4) (18.2-28.0) (9.6-13.3)
P value <0.001 0.289 0.232 0.306 <0.001 <0.001 <0.001
Programmed death-1 (PD-1)-related molecule expressions were measured on circulating CD4
+ and CD8
+ lymphocytes and monocytes in whole blood from
healthy volunteers (n = 49) and septic shock patients at day 1 to 2 (n = 37) and at day 3 to 5 (n = 56) after the onset of shock. Results are presented as mean
fluorescence intensity. A P value of less than 0.025 was considered statistically significant, and correction for the number of tests was performed (Mann-Whitney
U test). IQR, interquartile range.
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that typical sepsis-immune dysfunctions such as
decreased monocyte HLA-DR expression, decreased cir-
culating CD4
+ T-cell count, and increased percentage of
regulatory T cells [6] were associated with an increased
PD-1 expression on CD4
+ lymphocytes (and PD-L1 to a
lesser extent) and increased PD-1, PD-L1, and PD-L2
expressions on monocytes. Of note, during the review of
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Figure 3 PD-1-related molecule expressions on monocytes and
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on 26 survivors and 6 non-survivors at day 1 to 2 (D1-2) after the
onset of septic shock. Monocyte PD-1 (b) and PD-L2 (c) expressions
were measured at day 3 to 5 (D3-5) after the onset of shock on 15
patients who developed a secondary nosocomial infection during
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as (left) mean fluorescence intensities and (right) percentages of
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presented as box-plots as well as individual values. The Mann-
Whitney U test was performed. PD-1, programmed death-1; PD-L1,
programmed death-ligand 1; PD-L2, programmed death-ligand 2.
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Figure 4 Plasma IL-10 concentration and PD-1 expression in
patients with septic shock. (a) Plasma IL-10 concentration was
measured in survivors and non-survivors at day 1 to 2 (D1-2) (n =
23 and n = 6, respectively) and at day 3 to 5 (D3-5) (n = 24 and n =
5, respectively) after septic shock. Results are presented as box-plots
and as individual values, and horizontal lines represent medians. The
Mann-Whitney U test was performed. (b-d) Correlations between
increased plasma IL-10 concentration and increased PD-1 (b), PD-L1
(c), and PD-L2 (d) expressions on monocytes were calculated at D1-
2 and D3-5 in 29 patients with septic shock. The Spearman
correlation test was used to assess statistical significance. IL-10,
interleukin-10; PD-1, programmed death-1; PD-L1, programmed
death-ligand 1; PD-L2, programmed death-ligand 2.
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Page 7 of 11this article, a study including 19 patients with septic
shock confirmed that PD-1 expression on CD4
+ lym-
phocytes and PD-L1 expression on monocytes were ele-
vated in comparison with healthy volunteers [28].
Moreover, we observed a significant inverse correlation
between increased PD-1 and PD-L1 CD4
+ lymphocyte
expressions and decreased PHA-induced lymphocyte
proliferation in patients with septic shock. Such inverse
correlations have been described in patients with hepati-
tis B [29] and in patients with HIV [14]. Additionally,
we observed a significant correlation between increased
plasma IL-10 concentration and increased PD-1-related
molecule expressions on monocytes from patients with
septic shock. Recently, in an HIV-infected patient
cohort, such a correlation was described and implicated
in the reduced CD4
+ T-cell proliferation observed in
these patients [20]. In accordance with these observa-
tions, we recently showed not only that the increased
septic blood levels of IL-10 are reduced but also that
the rise in lipopolysaccharide-induced IL-10 release by
septic mouse macrophages is lost in animals that are
genetically deficient (knockout) in functional PD-1 [15].
Overall, our results therefore suggest a link between
increased PD-1-related molecule expressions and the
development of sepsis-induced immune dysfunctions.
Surprisingly, we found no PD-1 overexpression on cir-
culating CD8
+ T cells in septic patients. This is diver-
gent from the observations made in patients with HIV,
hepatitis B virus, or hepatitis C virus [13,25,26,29]. One
explanation may be that CD8
+ cells, which play a promi-
nent role in viral infections, may be less central to the
response patients make to septic shock. This is because
t h i sr e s p o n s ei st h o u g h tm a i n l yt ob ear e s p o n s et oa
bacterial challenge. Of note, Zhang and colleagues [28]
recently described an increased PD-1 expression on
CD8
+ lymphocytes in a small cohort of 19 septic shock
patients in comparison with healthy volunteers. Thus,
this observation deserves to be further examined in a
larger cohort of septic patients.
Of note, in our cohort, non-survivors displayed higher
monocyte PD-L1 expression in comparison with survi-
vors, and patients who went on to develop secondary
nosocomial infections had significantly higher PD-1 and
PD-L2 monocyte expressions in comparison with
patients who remained free of secondary infection. This
is consistent with data observed in a murine model of
sepsis, in which after the induction of polymicrobial sep-
tic shock by cecal ligation and puncture (CLP), PD-1
knockout mice showed a markedly improved capacity to
clear bacteria, both at the local (peritoneal lavage) and
the systemic (blood) level, in comparison with wild-type
mice [15]. Moreover, PD-L1 blockade significantly
improved survival, prevented sepsis-induced depletion of
lymphocytes, increased tumor necrosis factor-alpha and
IL-6 productions, decreased IL-10 production, and
enhanced bacterial clearance in mice after CLP [30].
Similar data were recently observed ex vivo in patients
with septic shock [28]. Importantly, we show here that
the PD-1 system not only may play a role in immune
dysfunction but also may be an indicator of septic mor-
tality and subsequent infectious episodes in septic
patients.
Increased expressions of co-inhibitory as well as
decreased expressions of co-stimulatory members of the
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ICU patients. In trauma patients, CTLA-4 and PD-1
expressions were elevated in anergic T cells [31]. Similar
results were observed at the mRNA level in trauma
patients with multiple organ dysfunction syndrome [32].
In mice, it was recently shown that B- and T-lympho-
cyte attenuator (BTLA) (another co-inhibitory molecule)
was induced at the early phase of Listeria monocytogenes
infection [33]. Moreover, CD3 expression on T lympho-
cytes was reduced in septic shock patients in compari-
son with healthy volunteers [34]. Similar decreased
expression was observed at the mRNA level in patients
developing sepsis or severe sepsis postoperatively [35]
and in trauma patients [36]. Finally, CD28 expression
(delivering a positive co-signal after ligation to B7.1 or
B7.2) was depressed in trauma patients’ anergic T cells
and may contribute to incomplete activation of these
cells [36]. In total, these alterations may play a major
role in lymphocyte anergy that has been observed in
ICU patients and that has been associated with
increased mortality and risk of nosocomial infections.
They could thus represent potential therapeutic targets
and associated markers to guide future immunothera-
peutic decisions [37].
The present study has some limitations. We could not
address the involvement of the PD-1 system in sepsis-
induced apoptosis. Indeed, PD-1 was first described as
being implicated in programmed cell death [38]. It was
also recently described that PD-1
+CD8
+ T cells were
more sensitive to both spontaneous and Fas-induced
apoptosis in comparison with PD-1
-CD8
+ T cells [14].
Most interestingly, it has recently been reported that
in vivo blockade of PD-1 could decrease T- and B-cell
apoptosis and improve survival in CLP-induced septic
mice [39]. However, given the technical difficulties
encountered in the measurement of apoptosis in clinical
samples, let alone in those of minimal-volume septic
shock patients’ whole blood samples that are already
dedicated to numerous assays [40], this aspect could not
be specifically addressed here and thus deserves to be
investigated in studies specifically dedicated to examin-
ing that process/index.
Conclusions
We describe here for the first time that PD-1/PD-L-
related molecule expression is markedly induced on cir-
culating cells of patients with septic shock. Moreover,
increased PD-1-related molecule expression appears to
be correlated with the development of immune dysfunc-
tions, secondary nosocomial infections, and death. We
believe that, although these findings need to be con-
firmed in a larger multicentered clinical study, our
results are in line with the recent commentary of
Hotchkiss and Opal [37], which proposes the use of
anti-PD-1 blocking antibodies in septic patients given
that these molecules are already being tested (and well
tolerated) in clinical trials in patients with cancer.
Although this hypothesis remains a speculation at the
moment and further functional studies are required to
understand the mechanism of action of PD-1-related
molecules in patients with septic shock, the PD-1 family
of receptor and ligands could represent a potential inno-
vative therapeutic strategy with which to restore
immune functions and may further alter morbidity/mor-
tality seen with sepsis, and this is in line with the con-
cept of tailored immunotherapy [41]. Through their
changing expression (alone or together with other mar-
kers), PD-1 molecules could give us insight into the
immune status of the septic individual as well as their
possible responsiveness to various established or novel
therapeutic approaches (or both) used in these critically
ill patients.
Key messages
￿ Programmed death-1 (PD-1)-related molecule
expressions are increased on circulating monocytes
and CD4
+ lymphocytes after septic shock in compar-
ison with healthy volunteers and trauma patients.
￿ Increased PD-1-related molecule expressions on
monocytes are significantly associated with increased
mortality and occurrence of secondary nosocomial
infections after septic shock.
￿ Augmented PD-1-relatedm o l e c u l ee x p r e s s i o n s
after septic shock are associated with immune dys-
functions such as decreased mitogen-induced lym-
phocyte proliferation and increased circulating
interleukin-10 concentration.
Abbreviations
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